Regentis Biomaterials Ltd.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsRegentis Biomaterials Ltd. is a clinical-stage regenerative medicine company developing degradable hydrogel implants for orthopedic tissue repair, listed on NYSE American under RGNT.
What they do
Regentis Biomaterials Ltd. is a regenerative medicine company focused on orthopedic treatments using its Gelrin platform, which consists of degradable hydrogel implants intended to regenerate tissue and restore health. The company is based in Israel and is traded on NYSE American. Its efforts are centered on developing innovative tissue repair solutions to enhance patients' quality of life.
Revenue drivers
- Gelrin platform — The company's primary focus is on its Gelrin platform, which uses degradable hydrogel implants for orthopedic tissue repair; the filing does not disclose revenue by product line.
Recent performance
For fiscal year 2025, Regentis reported a net loss of $13.6 million, compared to net income of $4.8 million in 2024 and a net loss of $4.1 million in 2023. Diluted EPS was negative $24.16 in 2025, versus positive $1.72 in 2024 and negative $24.09 in 2023. Operating cash flow was negative $1.4 million in 2025, compared with negative $0.6 million in 2024 and negative $1.2 million in 2023. As of December 31, 2025, the company had total assets of $7.6 million, total liabilities of $2.9 million, and shareholders' equity of $4.7 million, including $7.4 million in cash and cash equivalents.
Strategy
The company's stated strategy is to develop innovative tissue repair solutions using its Gelrin platform, with a current focus on orthopedic treatments. The filing does not provide specific details on recent strategic investments or partnerships.
Risks
- Clinical and regulatory risk — As a clinical-stage company, Regentis faces risks related to obtaining regulatory approvals for its Gelrin-based products.
- Funding and liquidity risk — With operating cash flow negative $1.4 million in 2025 and limited cash reserves, the company may need additional financing.
- Commercialization risk — The company has not yet commercialized its products, and market acceptance of its hydrogel implants is uncertain.
- Reliance on key personnel — The company depends on its senior management team, including CEO Dr. Ehud Geller, for strategic direction.
Outlook
The filing does not provide specific forward-looking guidance. Management's focus remains on advancing the Gelrin platform for orthopedic tissue repair.